Showing 2021-2030 of 2192 results for "".
- Long-Term Freedom from Seizure With Perampanel Treatmenthttps://practicalneurology.com/news/long-term-freedom-from-seizure-with-perampanel-treatment/2469455/In a post-hoc analysis, of the phase 3 FREEDOM study (NCT03201900), 62.5% of individuals treated with 4 to 8 mg/day of perampanel (Fycompa, Eisai Inc, Woodcliff Lake, NJ) achieved seizure freedom for 1 year. Participants in the study w
- Anxiety and Depression Prevalence in Children and Adolescents With Epilepsyhttps://practicalneurology.com/news/anxiety-and-depression-prevalence-in-children-and-adolescents-with-epilepsy/2469453/According to research presented virtually at American Epilepsy Society AES2020, children and adolescents with epilepsy are more likely to have anxiety and depression, including suicidal thinking, then previously considered. In a study of 119 children age 9 to 18 years, none of who
- Laser Thermal Ablation Therapy Brings Seizure Freedom to 54% of Children Treatedhttps://practicalneurology.com/news/laser-thermal-ablation-therapy-brings-seizure-freedom-to-54-of-children-treated/2469450/A new study being presented virtually at American Epilepsy Society AES2020 showed MRI-guided laser interstitial thermal therapy (MR-LITT) in children with medically refractory epilepsy, achieved seizure freedom for 54% 1 year after the procedure. Children treated (n=182) were age 14 months of age
- Vatiquinone Phase 3 Trial Initiated for Potential Treatment of Friedreich Ataxiahttps://practicalneurology.com/news/vatiquinone-phase-3-trial-initiated-for-potential-treatment-of-friedreich-ataxia/2469445/The registration-directed phase 3 MOVE-FA study (NCT04577352) evaluating vatiquinone (PTC743; PTC Therapeutics, South Plainfield, NJ) in children and young adults with Friedreich ataxia (FA) has b
- Potential Pediatric Use of New Migraine Therapieshttps://practicalneurology.com/news/potential-pediatric-use-of-new-migraine-therapies/2469437/Over the past 10 years multiple new treatments have been approved for use in adults. However, there has been little improvement in treatments specifically indicated for treatment of migraine in children, and very little data on the effects of these medications in children are available. At the Vi
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
- FDA Approves Lacosamide for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Usehttps://practicalneurology.com/news/fda-approves-lacosamide-for-primary-generalized-tonic-clonic-seizures-and-expanded-pediatric-use/2469432/The Food and Drug Administration (FDA) has approved lacosamide (Vimpat; UCB, Atlanta, GA) as adjunctive therapy for primary generalized tonic-clonic seizures (PGTCS) in children age 4 years or more and lacosamide injection for intravenous use. Results from a phase 3 study (
- Posttraumatic Stress Disorder Symptoms Increase Over Time After Concussionhttps://practicalneurology.com/news/over-time-the-effects-of-concussions-may-evolve-in-veterans/2469426/A study published in Neurology, suggest concussion (mild traumatic brain injury [mTBI]) symptoms can last as long as 5 years and evolve over time. The study evaluated and compared veterans (n=281) with an
- FDA Clears IND Application of Gene Therapy for Tay-Sachs and Sandhoff Diseaseshttps://practicalneurology.com/news/fda-clears-ind-application-of-gene-therapy-for-tay-sachs-and-sandhoff-diseases/2469420/The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a registrational study of adeno-associated viral (AAV) vector gene therapy (AXO-AAV-GM2; Axovant Gene Therapies, New York, NY) to treat individuals with Tay-Sachs disease and Sandhoff dis
- Society of Vascular and Interventional Neurology Launches Stroke Awareness Campaignhttps://practicalneurology.com/news/society-of-vascular-and-interventional-neurology-launches-stroke-awareness-campaign/2469413/The Society of Vascular and Interventional Neurology (SVIN) global campaign, Mission Thrombectomy 2020 (MT2020) has published a white paper, Mechanical Thrombectomy for Acute Stroke. Building Thrombectomy Systems of Care in Your Region: Why and How. The white paper is targeted towards health poli